Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Condition:   Covid19 Interventions:   Drug: BGB-DXP593;   Drug: Placebo Sponsor:   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials